NRX Pharmaceuticals, Inc. · NASDAQ:NRXP
NRX Pharmaceuticals — Investor Presentation (September 2022)
29 slides from NRX Pharmaceuticals's investor presentation, September 2022

Slide 1: Hope. Science. Life.
Hope. NASDAQ: NRXP Science. Life. NRx Pharmaceuticals, Inc. Corporate Presentation Sept 2022 NASDAQ: NRXP

Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation (this “Presentation”) is provided for informational purposes only. No representations or warranties, express or implied are given in, or in respect of, this Presentation. To the fullest extent permitted by law in no circumstances will NRx Pharmaceuticals, Inc.

Slide 3: Our Mission: We Bring Hope to Life
OUR MISSION We Bring Hope to Life Life-saving Medicines For People With Unmet Medical Needs Our medicines are based on newly-addressable molecular targets for illnesses that are not targeted by major pharmaceutical companies. 3

Slide 4: Leading the Way: Our Focus on Brain Health
LEADING THE WAY: OUR FOCUS ON BRAIN HEALTH There are no medicines today for people with suicidal bipolar depression. Someone attempts suicide every second, somewhere in the world, every 27 seconds in the US. Current antidepressants do not decrease suicidal ideation and are known to increase the risk

Slide 5: Leadership Team
Leadership Team Stephen Willard, JD – CEO & Director 30+ years of management of publicly traded biotechnology companies, with a strong background in law and finance. Served in CEO roles such as Cellphire Therapeutics, and Flamel Technologies, now Avadel Pharmaceuticals and has held leadership and di

Slide 6: Experienced Board of Directors
EXPERIENCED BOARD OF DIRECTORS Drug development, health policy, biosecurity 30 years senior executive experience Patrick Flynn, MBA CEO Health Dialog – exit to BUPA International Chair, Audit & Compensation Committees Bank of America (15 years), VP World Banking and Risk Management BS Finance, Whart

Slide 7: NRx R&D Pipeline: Multi-Billion Dollar Potential in Psychiatry
NRx R&D Pipeline: Multi-Billion Dollar Potential in Psychiatry Indication Compound Pre clinical Phase 1 Phase 2 Phase 3 Marketed Bipolar Depression & Suicidal Ideation Severe Bipolar Depression with Data readout expected NRX-100™ / NRX-101™ FDA SPA, Breakthrough, Biomarker letter of Support Acute Su

Slide 8: NRX-101
NRX-101™ The first oral, non-hallucinogenic, non-addictive medicine in development to treat Bipolar Depression in Patients with Acute suicidality* and Subacute suicidality** *ASIB - requiring hospitalization **SSIB – not requiring hospitalization

Slide 9: Why Target Suicidal Bipolar Depression
Why Target Suicidal Bipolar Depression Suicide kills ~50,000 Americans annually - Suicide is particularly high in bipolar disorder If you know two people with bipolar depression, one will attempt suicide, If you know five people with bipolar depression, one will succeed. 9

Slide 10: Suicidal Bipolar Depression: The Only Approved Treatment is ECT
Suicidal Bipolar Depression: The Only Approved Treatment is ECT No Approved Medicine No Good Choices Antidepressants (SSRIs) can increase suicidality Patients with suicidality are routinely excluded from clinical trials of other antidepressants Ketamine provides strong proof of concept but is known

Slide 11: Suicidal Bipolar Depression: The Unmet Need
Suicidal Bipolar Depression: The Unmet Need There is no approved drug for Suicidal Bipolar Depression. There are 100+ drugs for Major Depressive Disorder and, only a few for Bipolar Depression, and they all carry a Suicide Warning on the label. Drugs for Major Depressive Disorder (MDD) Drugs for Bip

Slide 12: Understanding the NMDA Receptor
Understanding the NMDA Receptor NRX-100 / NRX-101 to treat Bipolar Depression with Acute Suicidality. NRx-101 NMDA receptor antagonists have been known to have antidepressant effects for many years. Their use has been limited by potential for addiction, hallucination and Neurotoxicity. Recent eviden

Slide 13: Simultaneous Blockade of NMDA and 5-HT2A Blocks NMDA Side Effects
The Patented NRx Discovery: 90 patents around the world Simultaneous Blockade of NMDA and 5-HT2A Blocks NMDA Side Effects DCS (D-Cycloserine) Lurasidone blocks side-effects of 5HT2A Blocks side-effects of NMDA Psychosis Akathisia 13

Slide 14: NRX-101 Market Opportunity in Bipolar Depression with Suicidality
NRX-101 Market Opportunity Patients in Clinics and outpatient being treated for Bipolar Depression with in Bipolar Depression with Suicidality Suicidality FDA has granted Breakthrough Therapy Designation, a Special Protocol Agreement, and Biomarker Letter of Support for treatment US Bipolar Populati

Slide 15: NRX-101 Market Opportunity in Bipolar Depression
NRX-101 Market Opportunity in Bipolar Depression Patient Opportunity Patients in clinics and outpatient being treated for Bipolar Depression with Suicidality Adults With Bipolar 7,000,000 9-10% Patients With Suicidality 680,000 26% 74% $2.2 Billion ACUTE 180,000 Subacute Suicidality 500,000 Market P

Slide 16: Phase 2 Study Showed Effect of D-Cycloserine in Depression/Suicidality
Phase 2 Study showed effect of D-Cyclosrine in Depression/Suicidality If Phase 2 results are replicated in Phase 3, this will meet criteria for FDA approval. Mean 7.7 point benefit on MADRS (Primary Endpoint, P=.03) through day 42 vs. lurasidone. This difference is similar to or larger than that see

Slide 17: The STABIL-B Findings Are Supported by Independent Studies
The STABIL-B findings Are Supported by 3 Independent Studies A series of smaller studies have shown an improved antidepressant and anti-suicidal effect of DCS when added to 5HT2A / SSRIs Heresco-Levy et. al.(1) Kantrowitz et. al.(2) Chen et. al.(3) Treatment Resistant Depression Treatment Resistant

Slide 18: Expedited Approval Path through FDA
Expedited Approval Path through FDA FDA Reviewed the STABIL-B data and awarded Breakthrough Therapy Designation (BTD) together with a Special Protocol Agreement (SPA) The SPA letter signed by FDA allows NRx to apply for drug approval with a successful phase 3 trial of ~70 Patients using similar meth

Slide 19: Phase 2 Trial in Subacute Suicidality
Phase 2 Trial in Subacute Suicidality Targeting patients who are cared for in the outpatient setting, but are at risk for hospitalization (C-SSRS 3/4) Enrollment underway at ~ 10 study sites in the United States 19

Slide 20: Extending Findings of STABIL-B to Subacute Suicidality in Bipolar
Extending findings of STABIL-B to Subacute Suicidality in Bipolar Patients being seen in psychiatrists’ offices who do not yet need hospitalization Phase 2 trial of NRX-101 vs. Lurasidone without prior ketamine for stabilization. Patients with MADRS ≥ 30 (severe depression) and C-SSRS 3 or 4 (subacu

Slide 21: Magnetic Resonance Spectroscopy Supports Mechanism of Action
Magnetic Resonance Spectroscopy Supports Mechanism of Action NMDA antagonists, by stimulating brain glutamate are now known from nonclinical studies to “rewire” the brain by stimulating new connections between brain cells in the frontal cortex NRx is the only company in the psychiatry field to have

Slide 22: Path to Commercialization by 2024
Path to Commercialization by 2024 Technology and Manufacturing Transfer to USA completed in Q2 2022 Expecting to release first Phase 3/Commercial Scale drug in October 2022 Potential for Commercial Sales of NRX-101 by 2024 Options for either Direct Launch or license/partnering 22

Slide 23: NRx has Composition of Matter Patent Protection
NRx has Composition of Matter Patent Protection Patent Estate of 47 issued and 43 pending patents enables a platform of CNS drugs based on NMDA / 5HT2A Synergy. Five patent families, 90+ filed applications, 47 issued patents in US/EU/CN/JP/KO/AU. Protects NRX-101 to at least 2033 with potential for

Slide 24: NRX-101 for PTSD
NRX-101™ for PTSD Post-9/11, we have lost 4x more veterans and servicemembers to suicide than combat. No approved medicine for PTSD symptoms Only approved Medicine for PTSD-related Depression are SSRI’s that carry black box suicide warnings and do not affect Fear Memory

Slide 25: PTSD With and Without Suicidality
PTSD With and Without Suicidality Unmet Need 9+ Million 10% Have Suicidality EFFICACY • Higher % responders • Faster Onset SAFETY/ TOLERABILITY 1/3 With Severe >30K Veteran Deaths $5+ Billion Market Potential • Decrease or no increase in Suicidality Since 9/11 PTSD • Lower Side Effects Sources: Nati

Slide 26: Preclinical Support for NRX-101 in PTSD
Preclinical Support for NRX-101 in PTSD DCS-induced Reduced Fear Memory in WKY Rodent model of PTSD Depression in PTSD may be driven by pathways that are similar to those that drive depression in other conditions (NMDA and 5-HT2A. PTSD is unique in that “Fear Memory” with recurring images of traumat

Slide 27: Financials & Summary
Financials & Summary We apply innovative science to known molecules to develop life-saving medicines.

Slide 28: Financial Position
Financial Position NRXP Publicly traded Total Shares on NASDAQ NRxNRx Cash Cash Total Shares Outstanding: Position: Position: Outstanding: following SPAC merger $24.5 million ~67 million $24.5 million as ~67 million completed in as of 6/30/2022 shares as of of 6/30/2022 shares as of May 2021 8/1/202

Slide 29: Hope. Science. Life.
Hope. NASDAQ: NRXP Science. Life. NRx Pharmaceuticals, Inc. Corporate Presentation Sept 2022
Source: Internet Archive copy of nrxpharma.com
More decks from NRX Pharmaceuticals, Inc.
Investor Presentation (September 2026)20 slides · Sep 14, 2026
Investor Presentation (June 2026)21 slides · June 2026
Investor Presentation (October 2025)25 slides · October 2025
Investor Presentation (December 2024)32 slides · December 2024
Investor Presentation (July 2024)51 slides · July 2024
Investor Presentation (June 2023)34 slides · June 2023